STOCK TITAN
  1. Home
  2. News
  3. UCBJY

UCB SA - UCBJY STOCK NEWS

IMPACT
SENTIMENT
UCBJY : OTC
Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care
conferences
IMPACT
SENTIMENT
UCBJY : OTC
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
partnership
IMPACT
SENTIMENT
UCBJY : OTC
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB Showcases Key Rheumatology Data at ACR Convergence 2021
IMPACT
SENTIMENT
SHCR : Nasdaq UCBJY : OTC
Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit
conferences clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy
IMPACT
SENTIMENT
UCBJY : OTC
UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab
IMPACT
SENTIMENT
UCBJY : OTC
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Stock UCBJY logo
UCB SA

OTC:UCBJY

UCBJY Rankings

#794 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

UCBJY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Pharmaceuticals: Major, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Belgium
Anderlecht